Cutting-edge technologies are the driving force behind our strong research and development pipeline
Although tremendous progress has been made in the prevention of infectious diseases, improvements are needed to reduce the time lag between the declaration of public health emergencies and availability of effective medical technologies that can be used to save lives.
Our innovative vaccine technology platforms – the PER.C6® and AdVac® technologies – offer real hope for the accelerated development of vaccines, which would help the global health community better prepare for possibly life-threatening infectious disease outbreaks in the future.
During the Ebola virus epidemic in West Africa, Janssen responded by accelerating Ebola virus vaccine development and scale up, resulting in the manufacturing of more than two million monovalent vaccine regimens in less than one year – utilizing PER.C6®.
|PER.C6® Technology||AdVac® Technology|
This technology provides a cost-effective manufacturing system for high-yield, faster and large-scale production of vaccines and monoclonal antibodies.
It is especially useful for vaccine manufacturing that requires the production of hard-to-grow viruses and could hold the key to making such vaccines affordable for the whole world.
A technology based on the development and production of adenovirus vectors (gene carriers).
It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening infectious diseases.